Le Lézard
Classified in: Health
Subject: CCA

Neovasc to Host Third Quarter 2017 Conference Call


NASDAQ, TSX: NVCN

VANCOUVER, Nov. 10, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call that same day at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive Officer, and Mr. Chris Clark, Chief Financial Officer. A question and answer session will follow the corporate update.

Conference Call Details


DATE:

Tuesday, November 14, 2017

TIME:

4:30 pm ET

DIAL-IN NUMBER:

888 390 0605 or 416 764 8609

 

A link to the live audio webcast of the conference call will also be available on the Presentations and Events page of the Investors section of Neovasc's website at www.neovasc.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.  

A recording of the call will be available for 72 hours by calling 888 390 0541 or 416 764 8677 and using passcode 762334#.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducertm, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiaratm, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.


These press releases may also interest you

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

at 17:31
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...

at 17:31
DelveInsight's Corneal Implant Market...

at 17:26
In observance of National Infertility Awareness Week (April 21-27, 2024), Inception Fertilitytm, a global leader of fertility services, and The Prelude Network®, Inception's clinical network and the largest network of fertility providers in North...



News published on and distributed by: